Efavirenz Concentrations and Probability of HIV Replication in Children

Pediatr Infect Dis J. 2015 Nov;34(11):1214-7. doi: 10.1097/INF.0000000000000854.

Abstract

In 188 HIV-infected children receiving efavirenz, a lower mid-dose (C12) was associated with a higher risk of HIV-1 viral load >400 copies/mL (P = 0.03). Simulations for a normalized population receiving US Food and Drug Administration weight-band dosing predicted that 15% of children would have a C12 below target threshold (<1.0 mg/L) with a 23% risk of viral replication.

MeSH terms

  • Alkynes
  • Benzoxazines / blood*
  • Benzoxazines / pharmacokinetics
  • Benzoxazines / pharmacology
  • Benzoxazines / therapeutic use
  • Child
  • Cohort Studies
  • Cyclopropanes
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • HIV-1 / drug effects
  • Humans
  • Male
  • Reverse Transcriptase Inhibitors / blood*
  • Reverse Transcriptase Inhibitors / pharmacokinetics
  • Reverse Transcriptase Inhibitors / pharmacology
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Viral Load / drug effects*

Substances

  • Alkynes
  • Benzoxazines
  • Cyclopropanes
  • Reverse Transcriptase Inhibitors
  • efavirenz